abstract: Aim. We presented the case of a @entity0 with @entity4 ( @entity4 ) to highlight issues that need to be considered in planning long-haul flight and problems that may arise during the flight. Case. The pediatric intensive care unit (PICU) received a @entity0 with @entity4 ( @entity4 ) on nocturnal ventilatory support who travelled to Hong Kong on a make-a-wish journey. He was diagnosed with central @entity3 and had been well managed in Canada. During a long-haul aviation travel, he developed @entity1 and desaturations. The @entity0 arrived in Hong Kong and his @entity1 persisted. He was taken to a PICU for management. The @entity0 remained well and investigations revealed no pathogen to account for his @entity2 . He went on with his make-a-wish journey. Conclusions. Various issues of travel medicine such as equipment, airline arrangement, in-flight ventilatory support, travel insurance, and @entity2 are explored and discussed. This case illustrates that long-haul air travel is possible for @entity0 with respiratory compromise if anticipatory preparation is timely arranged.

title: Central @entity3 : A Case Study of Issues Associated with Travel Medicine and XXXX .

answer: @entity2


abstract: AIM: To investigate the efficacy and safety of @entity1 ( @entity7 )-based combination chemotherapies for the treatment of advanced @entity4 . METHODS: Clinical trials were identified by searching scientific literature databases (PubMed, EMBASE and the Cochrane Library) for studies published between 1975 and 2013. Two reviewers independently evaluated the relevant studies and manually searched references from these reports to locate additional eligible studies. The disease response and control rates, progression-free and overall survivals, and the grade 3-4 @entity2 were evaluated by a meta-analysis. Odds-ratios (ORs) of the disease response and control rates and grade 3-4 @entity2 , and the mean difference (MD) of both progression-free and overall survivals were calculated and used for statistical analysis. RESULTS: Seven randomized trials with a total of 858 @entity0 were selected and included in the final analysis. The studies were divided into subgroups based on the chemotherapy regimens, including @entity7 -based and non- @entity7 -based chemotherapies. The overall analyses revealed that the @entity0 treated with @entity7 -based combination chemotherapy had significantly higher disease response rates [OR = 1.69, 95% confidence interval (CI): 1.17-2.43; P = 0.01], a longer progression-free survival (MD = 1.95, 95%CI: 0.90-3.00; P = 0.00) and a longer overall survival (MD = 1.85, 95%CI: 0.26-3.44; P = 0.02). A higher incidence of grade 3-4 hematological @entity2 , including @entity6 (OR = 2.98, 95%CI: 1.44-6.20; P = 0.00), @entity3 (OR = 2.96, 95%CI: 1.79-4.92; P = 0.00) and @entity5 (OR = 2.80, 95%CI: 1.39-5.64; P = 0.00) was found in the @entity7 -based combination chemotherapy group compared with the @entity7 monotherapy and non- @entity7 -based chemotherapy groups. CONCLUSION: @entity7 -based combination chemotherapy is a potential first-line treatment for advanced @entity4 as a result of improved survival, though with additional @entity2 .

title: Efficacy and safety of @entity1 -based chemotherapies in XXXX : a meta-analysis.

answer: @entity4


abstract: BACKGROUND: Annually,    80,000 Americans receive guideline-based primary prevention @entity4 ( @entity4 ), but appropriate firing rates are low. Current selection criteria for @entity4 rely on left ventricular ejection fraction, which lacks sensitivity and specificity. Because scar-related myocardial tissue heterogeneity is a substrate for life-threatening @entity5 , we hypothesized that cardiac magnetic resonance identification of myocardial heterogeneity improves risk stratification through (1) its association with adverse @entity3 independent of clinical factors and biomarker levels and (2) its ability to identify particularly high- and low-risk subgroups. METHODS AND RESULTS: In 235 @entity0 with chronic @entity2 with a left ventricular ejection fraction of  <=35% undergoing clinically indicated primary prevention @entity6 implantation, @entity9 -enhanced cardiac magnetic resonance was prospectively performed to quantify the amount of heterogeneous myocardial tissue (gray zone [GZ]) and dense core scar. Serum high-sensitivity @entity7 (hsCRP) and other biomarkers were assayed. The primary end point was appropriate @entity6 shock for @entity8 or @entity1 , which occurred in 45 (19%) @entity0 at a 3.6-year median follow-up. On univariable analysis, only diuretics, hsCRP, GZ, and core scar were associated with outcome. After multivariable adjustment, GZ and hsCRP remained independently associated with outcome (P<0.001). @entity0 in the lowest tertile for both GZ and hsCRP (n=42) were at particularly low risk (0.7% per year event rate), whereas those in the highest tertile for both GZ and hsCRP (n=32) had an event rate of 16.1% per year, P<0.001. CONCLUSIONS: In a cohort of primary prevention @entity6 candidates, combining a myocardial heterogeneity index with an inflammatory biomarker identified a subgroup with a very low risk for adverse @entity3 , including @entity5 . This novel approach warrants further investigation to confirm its value as a clinical risk stratification tool. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00181233.

title: Combined cardiac magnetic resonance imaging and @entity7 levels identify a cohort at low risk for defibrillator firings and XXXX .

answer: @entity1


abstract: OBJECTIVE: To investigate whether @entity3 ( @entity3 ) exon 5 and @entity2 ( @entity2 ) gene polymorphisms can be used as markers of susceptibility to febrile @entity1 in @entity0 . METHODS: @entity0 were divided into 2 groups: those with febrile @entity1 (group 1; n = 51) and normal control subjects (group 2; n = 83). Polymorphisms for @entity3 exon 5 and @entity2 gene polymorphisms were detected by polymerase chain reaction. Genotypes and allelic frequencies for @entity3 exon 5 and @entity2 gene polymorphisms in both groups were compared. RESULTS: Genotype and allele frequencies for @entity3 exon 5 in both groups were not significantly different. Proportions of E1 homozygotes and @entity4 heterozygotes for @entity3 exon 5 were 50 (98.1%) and 1 (1.9%), respectively, in group 1 and 82 (98.8%) and 1 (1.2%), respectively, in group 2. Frequencies of alleles E1 and E2 for @entity3 exon 5 were 101 (99.0%) and 1 (1.0%), respectively, in group 1 and 165 (99.4%) and 1 (0.6%), respectively, in group 2. Genotype proportions and allele frequencies for @entity2 between groups were significantly different. Proportions of genotypes I/I and I/II for @entity2 were 49 (96.1%) and 2 (3.9%) in group 1 and 69 (83.1%) and 14 (16.9%) in group 2. Frequencies of alleles I and II for @entity2 were 100 (98.0%) and 2 (2.0%) in group 1 and 152 (91.6%) and 14 (8.4%) in group 2. CONCLUSIONS: The @entity2 allele I is associated with a higher susceptibility to febrile @entity1 , which may become a useful marker for predicting the development of febrile @entity1 . The @entity3 exon 5 gene polymorphisms are not a useful marker for predicting the susceptibility to febrile @entity1 .

title: Polymorphisms for @entity3 exon 5 and interleukin 1 receptor antagonist in Taiwanese XXXX with febrile @entity1 .

answer: @entity0


abstract: OBJECTIVE: To study the role of mechanical, infectious, and inflammatory factors inducing @entity8 in @entity11 ( @entity11 ), an @entity3 characterised by attacks of @entity5 and @entity7 , @entity6 , and sensory alterations of the shoulder girdle and upper limb muscles. METHODS: Four @entity0 from separate kindreds with @entity11 were evaluated. Upper extremity nerve biopsies were obtained during attacks from a @entity0 of each kindred. In situ hybridisation for common viruses in nerve tissue and genetic testing for a @entity10 ( @entity10 ; @entity1 ) were undertaken. Two @entity0 treated with intravenous @entity9 had serial clinical and electrophysiological examinations. One @entity0 was followed prospectively through pregnancy and during the development of a stereotypic attack after elective caesarean delivery. RESULTS: Upper extremity nerve biopsies in two @entity0 showed prominent perivascular inflammatory infiltrates with vessel wall disruption. Nerve in situ hybridisation for viruses was negative. There were no tomaculous nerve changes. In two @entity0 intravenous @entity9 ameliorated symptoms ( @entity5 ), but with tapering of @entity4 dose, signs and symptoms worsened. Elective caesarean delivery did not prevent a typical postpartum attack. CONCLUSIONS: @entity2 , probably immune, appears pathogenic for some if not all attacks of @entity11 . Immune modulation may be useful in preventing or reducing the @entity8 , although controlled trials are needed to establish efficacy, as correction of the mutant gene is still not possible. The genes involved in immune regulation may be candidates for causing @entity3 .

title: @entity2 and @entity8 in XXXX .

answer: @entity11


abstract: Enlargement of preexisting @entity4 during pregnancy is well documented, but this phenomenon is unusual for nonendocrine @entity4 such as @entity3 . Only six cases of @entity3 have been reported as presenting during pregnancy. The authors describe a 19-year-old @entity0 who presented with @entity6 and @entity7 caused by an intrasellar mass. Seven months later, when she was 20 weeks pregnant, the @entity0 developed sudden @entity2 . Emergency transsphenoidal surgery was performed to restore visual function, and the @entity1 was found to be a @entity3 . The @entity0 had spontaneous labor and delivered a healthy @entity0 at term. The @entity1 recurred 4 years later, during her second pregnancy, and was again entirely removed via a second transsphenoidal approach. She again had a normal term delivery. During the 5-year follow-up period she has demonstrated no @entity2 . Control magnetic resonance images have revealed no recurrence of the @entity1 . The transsphenoidal approach seems to be the safest procedure to use during pregnancy to achieve an immediate @entity5 and to preserve pituitary function.

title: Rapid enlargement and recurrence of a preexisting XXXX during the course of two pregnancies. Case report.

answer: @entity3


abstract: Neuronal nicotinic @entity2 receptors of chromaffin cells in the adrenal medulla are physiologically activated by @entity2 to mediate @entity5 release into the bloodstream. The present study examined the subunit composition and functional properties of @entity1 chromaffin cell neuronal nicotinic @entity2 receptors using molecular biology, immunocytochemistry and whole-cell patch-clamp. Reverse transcription-polymerase chain reaction analysis indicated the presence of alpha2, alpha3, alpha4, alpha5, alpha7, beta2 and beta4 transcripts (alpha6 and beta3 could not be detected). Immunocytochemistry revealed most cells positive for alpha3, beta2, beta4 and alpha5 proteins. Few cells were immunoreactive for alpha2 and alpha4, while none was for alpha7. At single-cell level, colocalization could be demonstrated for alpha3alpha5 and alpha4beta2. Western blot analysis confirmed antibody specificity for alpha3, alpha4, alpha5, beta2 and beta4 subunits. Inward currents elicited by @entity3 pulses were insensitive to alpha-bungarotoxin and low doses of @entity4 , demonstrating lack of functional alpha7 receptors. Partial block of @entity3 currents was observed with either AuIB alpha-conotoxin (selective against alpha3beta4 receptors) or MII alpha-conotoxin (selective against alpha3beta2 receptors). With high concentrations of co-applied toxins, antagonism occlusion developed, suggesting loss of subunit selectivity. Antagonism by @entity6 summated nonlinearly with AuIB and MII inhibition, confirming heterogeneity of neuronal nicotinic @entity2 receptor block. The present results suggest that the most frequently encountered receptors of @entity1 chromaffin cells should comprise alpha3beta4, alpha3beta2 with the addition of alpha5 subunits. Because of the prevailing subunit composition, @entity1 chromaffin cell neuronal nicotinic @entity2 receptors are suitable models, particularly for the alpha3beta4 subclasses of @entity0 brain receptors recently demonstrated in discrete cerebral areas.

title: Molecular biology and electrophysiology of neuronal nicotinic receptors of XXXX chromaffin cells.

answer: @entity1


abstract: BACKGROUND: The interval @entity1 rate is an important parameter for determining the sensitivity of a screening procedure and the screening interval. We evaluated the time and mechanism of detection and the stage distribution of @entity2 diagnosed during a 4-year screening interval. METHODS: We determined the rate of @entity1 and the sensitivity of the screening protocol (involving @entity3 , digital rectal and transrectal ultrasound examinations) in a cohort of 17 226 @entity0 (8350 on the screened arm, 8876 on the control arm) enrolled consecutively on the European Randomized Study of Screening for @entity2 . @entity0 on the screened arm received a first screen between October 1993 and December 1996 and a scheduled second screen 4 years later. @entity2 detected in @entity0 enrolled on the control arm over the same 4-year period and, between screens, in @entity0 on the screened arm, were identified by linkage to the Dutch national @entity1 registry. RESULTS: During the first screen, 412 @entity2 were detected. During the subsequent 4-year period, 135 @entity1 were diagnosed in @entity0 in the control arm and 25 @entity1 were diagnosed in @entity0 in the screened arm. Seven of the 25 @entity1 were diagnosed in @entity0 who had refused a recommended biopsy at their initial screen. Of the remaining 18 @entity1 , all were classified as stage @entity5 -C or @entity4 and none were poorly differentiated or metastatic. The rate of @entity1 relative to the number of @entity1 in the control group was 18.5% (25/135), or 13.3% (18/135), if the seven who refused an initial biopsy were excluded. The sensitivity of the screening protocol was 79.8% when considering all 25 @entity1 and 85.5% when considering 18 @entity1 . CONCLUSION: The interval @entity1 rate with a 4-year screening interval was low, confirming that the screening procedure has a high sensitivity and that the 4-year screening interval is reasonable.

title: Interval carcinomas in the European Randomized Study of Screening for XXXX (ERSPC)-Rotterdam.

answer: @entity2


abstract: Infection is the most serious complication arising in long-term continuous ambulatory peritoneal dialysis (CAPD), specifically @entity2 . The initial weeks after implantation is the crucial period during which bacterial colonization of the catheter results in maximal morbidity, with @entity3 being the most virulent organism. We developed an antimicrobial-impregnated CAPD catheter by impregnating the cuff and tubing with @entity4 , @entity5 , and @entity6 in a polymer matrix. The antimicrobial spectrum and duration were shown by measuring zones of inhibition to various bacteria and fungi over the course of 5 to 10 days. Activity also was assessed subsequent to soaking in trypticase soy broth containing 20% bovine serum over the course of 1, 3, and 7 days. Significant antimicrobial activity was shown against all organisms tested for, with particular efficacy against gram-positive bacteria. Catheters were implanted in @entity1 followed by inoculation of the exit site with @entity3 . Seven days postimplantation, 0% of the impregnated catheters were colonized intraperitoneally compared with 100% of the control catheters. Similarly, 12.5% of the impregnated catheters were colonized at the exit site, whereas 100% of the controls were colonized. Histologic analysis showed that this combination and concentration of antimicrobials did not retard healing or cause increased @entity0 compared with control catheters after 3, 10, and 24 days postimplantation in noninoculated @entity1 .

title: Evaluation of an antimicrobial-impregnated continuous ambulatory peritoneal dialysis catheter for infection control in XXXX .

answer: @entity1


abstract: BACKGROUND: The long-term complications of immunosuppressive therapy such as @entity1 , @entity9 , and @entity2 are a major source of morbidity in liver transplant recipients. In this prospective, randomized, open-label study we completely withdrew @entity6 (PRED) 14 days after liver transplantation in an effort to decrease these metabolic complications. @entity0 were maintained on @entity7 ( @entity11 ) in combination with either @entity5 (CsA; Neoral formulation) or @entity10 ( @entity13 ). Thus, we also were able to compare @entity8 to @entity13 in @entity0 not receiving PRED with respect to efficacy, @entity3 , and effect on posttransplant metabolic complications. METHODS: A total of 71 @entity0 were randomized to receive either @entity13 - @entity11 (n=35) or CsA- @entity11 (n=36) after liver transplantation and were analyzed for @entity0 and graft survival. Fifty-eight @entity0 continued the immunosuppressive protocol for at least 6 months after transplantation and were analyzed for the incidence of acute rejection and the prevalence of @entity1 , @entity2 , and @entity9 . RESULTS: The 6-month @entity0 survival rates were 94.4% for CsA- @entity11 and 88.6% for @entity13 - @entity11 . Corresponding 6-month graft survival rates were 88.7% and 85.71% with no immunologic graft losses in either group. The incidence of biopsy-proven acute rejection was 46% for CsA- @entity11 and 42.3% for @entity13 - @entity11 . Six @entity0 were converted from CsA to @entity13 (four for recurrent rejection) and seven @entity0 were converted from @entity13 to CsA (four for @entity12 ). Only one @entity0 (in the @entity13 - @entity11 group) developed new-onset posttransplant @entity1 . In contrast, four of eight @entity0 in the CsA- @entity11 group who were @entity1 before transplant became nondiabetic in the first 3 months after transplant. The mean serum @entity4 level was significantly lower in the @entity13 - @entity11 group than in the CsA- @entity11 group (145.2+/-41.8 mg/dl and 190.3+/-62.2, respectively; P<0.001) and the incidence of @entity2 was lower in the @entity13 - @entity11 group (12% vs. 30.3% in the CsA- @entity11 group, P<0.01). Both groups had a lower incidence of metabolic complications compared with a historical group (n=100) maintained on CsA and PRED (10 mg/day at 6 months). CONCLUSIONS: @entity11 in combination with either @entity13 or CsA allows withdrawal of @entity14 days after liver transplantation with a moderate rejection rate and no immunologic graft losses. Early PRED @entity1 , @entity9 , and @entity2 , but @entity0 maintained on @entity13 have lower serum @entity4 levels and a lower incidence of @entity2 than CsA-treated @entity0 .

title: XXXX withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of @entity5 and @entity10 .

answer: @entity6


abstract: PURPOSE: To determine in a prospective study the efficacy, @entity1 , and long-term outcome of up-front allogeneic stem-cell transplantation (allo- @entity4 ) in @entity2 ( @entity2 ). @entity0 AND METHODS: In the prospective phase III study by the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), HOVON 24 @entity2 , 53 @entity0 with an HLA-identical sibling (median age at transplantation, 48 years; range, 31 to 56 years) were allocated to a partial T-cell-depleted allo- @entity4 after induction therapy. RESULTS: The overall response rate after allo- @entity4 was 89% (47 of 53 @entity0 ), including the 19% of @entity0 (10 of 53 @entity0 ) with a complete remission (CR). Five @entity0 achieved a CR only after allo- @entity4 . Five (71%) of seven primary refractory @entity0 obtained a response to allo- @entity4 , all of whom had a partial remission. With a median follow-up of 38 months (range, 25 to 61 months), 20 @entity0 are alive since allo- @entity4 and 33 @entity0 have died (14 from progressive disease, 18 from treatment-related mortality [TRM], and one from another cause). Occurrence of @entity3 grades 2 to 4 predicted for higher TRM in a time-dependent analysis. The median progression-free survival time after allo- @entity4 was 17 months. Median overall survival time after allo- @entity4 was 25 months, or 29 months from the start of therapy. Only three @entity0 are in continuing CR, indicating that the potential cure rate of this approach is, at best, 6%. CONCLUSION: This first prospective evaluation of up-front allo- @entity4 of @entity2 in a multicenter setting does not support the use of T-cell-depleted myeloablative allo- @entity4 as part of first-line therapy.

title: Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of @entity2 : a prospective evaluation of @entity0 treated in the phase III study HOVON 24 XXXX .

answer: @entity2


abstract: PURPOSE: To investigate the effectiveness of a standard Cardiac Rehabilitation Programme (CRP) and an @entity1 ( @entity1 ) for @entity0 with @entity2 ( @entity2 ). METHOD: Subjects with @entity2 discharged from hospitalization were invited to participate in a 6-week CRP followed by a 12-week @entity1 . Outcome variables included New York Heart Association functional classification, distance covered in a 6 minute-walk distance (6MWD), health-related quality of life (HRQOL) questionnaire and rate of hospital re-admission. RESULTS: Of 58 invited subjects, 26 completed the CRP and 18 continued with @entity1 . Subjects who participated in CRP and @entity1 showed superior improvement in 6MWT and HRQOL scores (p < 0.05) compared with those who did not participate in either program (control). Subjects who continued with the @entity1 demonstrated further improved performance compared with those who participated in CRP only. Of those re-admitted to hospital with symptoms associated with @entity2 , 73% were @entity0 from the control group; 21% were those who completed the CRP and 6% were @entity0 who completed the @entity1 . CONCLUSION: CRP is effective in improving functional capacity, HRQOL and reduces hospital readmission for @entity0 with @entity2 . An @entity1 provides opportunities for further improvement in outcome. However there is a need to improve the @entity0 participation rate of the programme in the Chinese community.

title: Clinical outcomes of a Cardiac Rehabilitation and Maintenance Program for Chinese @entity0 with XXXX .

answer: @entity2


abstract: @entity1 treatment (BHT) is an intensive care characterized by simultaneous managements of various vital signs, such as @entity3 ( @entity3 ) and pressure ( @entity2 ), of the severe neuropatient. Medical treatments including therapeutic ambient cooling and diuresis are separately carried out based on the experience of the medical staff involved in the clinical management of various pathophysiological processes, such as thermodynamics, hemodynamics and pharmacokinetics. However, no special attention has been paid to the interactions among these subsystems in @entity5 because of the lack of theoretical knowledge. Therefore, quantitative analyses using an integrated model of various physiological processes and their interactions are of pressing need. In the present paper, we propose a general compartmental model to describe the pathophysiological processes of the three aforementioned dynamics, on account of the dynamical analogy of temperature, pressure and concentration. The model is verified by the agreement of model-based simulation results with clinical evidence. Based on responses of the integrated model to various stimuli, a transfer function matrix is identified to linearly approximate the characteristic interrelationships between medical treatments (ambient cooling and diuresis) and the vital signs ( @entity3 and @entity2 ). Then a controller that decouples ambient cooling and diuresis is proposed for efficient management of @entity3 and @entity2 , enhancement of hypothermic decompression and reduction of diuretic dosage. Decoupling control simulation indicates that @entity3 and @entity2 of the integrated model, representing a @entity0 under @entity4 , can be simultaneously regulated by a single PID controller for ambient cooling and another for diuresis. The proposed decoupler effectively establishes hypothermic decompression, reduces the dosage of diuretic and improves @entity2 management. Theoretical analyses of the integrated model and decoupling control of @entity3 and @entity2 provide insights into the intensive care of various pathophysiological processes in @entity0 undergoing BHT.

title: An integrated model of thermodynamic-hemodynamic-pharmacokinetic system and its application on decoupling control of XXXX and pressure in brain @entity5 treatment.

answer: @entity3


abstract: UNASSIGNED: The invasive and lethal nature of @entity3 the continuous identification of molecular targets and search of efficacious therapies to inhibit GBM growth. The GBM resistance to chemotherapy and radiation it is attributed to the existence of a rare fraction of @entity0 stem cells (CSC) that we have identified within the @entity0 core and in peritumor tissue of GBM. Since @entity2 pathway is a potential therapeutic target in @entity6 , earlier we highlighted that pharmacological inhibition of @entity2 signalling by y-secretase inhibitor-X (GSI-X), reduced cell growth of some c-CSC than to their respective p-CSC, but produced negligible effects on cell cycle distribution, apoptosis and cell invasion. In the current study, we assessed the effects of @entity5 -targeted shRNA, a @entity2 gene target, specifically on GBM CSC refractory to GSI-X. Depletion of @entity5 protein induces major changes in cell morphology, cell growth rate and in the invasive ability of shHes1-CSC in response to growth factor EGF. shHes1-CSC show a decrease of the stemness marker Nestin concurrently to a marked increase of neuronal marker @entity8 compared to pLKO.1-CSC. Those effects correlated with repression of @entity4 protein and modulation of @entity7 phosphorylation at Y705 and S727 residues. In the last decade @entity7 has gained attention as therapeutic target in @entity0 but there is not yet any approved @entity7 -based @entity1 therapy. Herein, we report that exposure to a @entity9 inhibitor, induced apoptosis either in shHes1-CSC or control cells. Taken together, @entity5 seems to be a favorable target but not sufficient itself to target GBM efficaciously, therefore a possible pharmacological intervention should provide for the use of anti- @entity9 drugs either alone or in combination regimen.

title: The interference of @entity2 target @entity5 affects cell growth, differentiation and invasiveness of XXXX stem cells through modulation of multiple oncogenic targets.

answer: @entity3


abstract: Postoperative radiotherapy (PRT) is widely advocated for @entity0 with @entity2 of the head and neck that are considered to be at high risk of recurrence after surgical resection. The aims of this study were to evaluate the treatment outcomes of PRT for @entity0 with @entity1 and to identify the value of several prognostic factors. We reviewed the records of 256 @entity0 treated for @entity2 between January 1993 and December 2005. Disease-free survival (DFS) and @entity3 ( @entity3 ) were estimated using the Kaplan-Meier method. Log-rank test was employed to identify significant prognostic factors for DFS and @entity3 . The Cox proportional hazards model was applied to identify covariates significantly associated with the aforementioned endpoints. Our results showed the 3-, 5-, and 10-year DFS for all @entity0 were 69.9%, 59.5%, and 34.9%, respectively. The 3-, 5-, and 10-year @entity3 rates were 80.8%, 68.6%, and 38.8%, respectively. Significant prognostic factors for both DFS and @entity3 on univariate analysis were grade, primary site, T stage, N stage, overall stage, @entity4 , overall treatment times of radiation, the interval between surgery and radiotherapy, and radiotherapy equipment. Favorable prognostic factors for both DFS and @entity3 on multivariate analysis were lower overall stage, no cervical @entity4 , and using 60Co as radiotherapy equipment. In conclusion, our data suggest that lower overall stage, no cervical @entity4 , and using 60Co as radiotherapy equipment are favorable prognostic factors for DFS and @entity3 and that reducing the overall treatment times of radiation to 6 weeks or less and the interval between surgery and radiotherapy to less than 3 weeks are simple measures to remarkably improve treatment outcome.

title: Treatment results and prognostic factors of XXXX undergoing postoperative radiotherapy for @entity2 .

answer: @entity0


abstract: @entity4 ( @entity4 ) is a malignancy of @entity5 (+) B cells. This B-cell lineage is established during ontogeny and replenished by the process of self-renewal. Spontaneous and induced @entity3 that frequently affect this lineage are thought to arise as a result of the frequent cell division required to maintain the population throughout adulthood and in response to repeated exposure to environmental antigens. In a series of bone marrow transplant (BMT) experiments performed in B6D2F1 @entity0 , @entity6 occurred in recipients of serially transplanted syngeneic bone marrow. This study was therefore designed to determine the frequency and phenotype of the observed @entity3 . Male donor cells were initially transplanted into lethally irradiated female hosts and secondary (2 degrees ) BMT was performed at 3 months. At 1, 2, 3 and 16 months following primary (1 degrees ) BMT, and when 2 degrees BMT recipients developed @entity3 , animals were sacrificed and their tissues extensively examined. These analyses confirmed a host-derived @entity5 (+) transplantable @entity6 that was initiated in 50% of 1 degrees BMT recipients. With serial passage, the @entity3 became more @entity1 and lost @entity5 expression, suggesting transformation to a high-grade @entity3 / @entity2 . This previously unreported observation suggests that the combination of radiation and subsequent serial transplantation induces a proliferative stress to the host B-cell compartment that is causative in leukaemic transformation.

title: In vivo expansion of the endogenous B-cell compartment stimulated by radiation and serial bone marrow transplantation induces XXXX in @entity0 .

answer: @entity6


abstract: UNASSIGNED: @entity11 .5% of all @entity7 . While they typically arise in the sphenoid wing, convexity MEP are comparatively rare and are often confused with @entity4 , @entity5 , @entity9 , or @entity3 , with very little information published in the literature. We conducted a literature review on PubMed of English-only articles using a keyword search. All studies that described reports of convexity MEP were reviewed for @entity0 demographics, presenting symptoms, radiological reports, surgical management, recurrence rates, histopathological presentation, post-operative complications, and follow-up. This resulted in 12 papers comprising 22 cases of convexity MEP. Seventeen (77%) of the 22 @entity0 were female with an average age of 53.2years. Intitial presenting symptoms included @entity2 in 12/20 (60%), @entity6 in 5/20 (25%), and visual symptoms in 1/20 (5%). Of the 14 @entity0 who underwent surgical resection, only four were reported as gross total resection. Twelve reports had associated pathology reports, with all 12 @entity1 graded as World Health Organization Grade I. Convexity MEP, while rare, present a challenge with regard to correct diagnosis and subsequent resection. The easier accessibility of these @entity7 predicts higher surgical success rates and incidence of total resection, though care must be taken to ensure @entity1 , dural attachments, and any overlying @entity10 bone. Though @entity8 is frequently observed with this variant of @entity7 , it is neither exclusive nor wholly indicative of MEP. Due to its rarity in both clinical practice and the literature, further studies are warranted to identify modern imaging means to correctly diagnose this condition.

title: Surgical limitations in XXXX en-plaque: Is radical resection necessary?

answer: @entity7


abstract: BACKGROUND: Epidemiological changes and the ongoing expansion of the diagnostic armamentarium warrant a regular update of the spectrum of diseases that present as prolonged febrile illnesses. METHODS: We prospectively collected a series of 290 immunocompetent @entity0 referred to our university hospital between 1990 and 1999 with a @entity3 (temperature >38.3 degrees C) of uncertain cause, lasting at least 3 weeks. @entity0 were categorized in 4 groups according to the timing of diagnosis: early diagnosis (within 3 in-hospital days or 3 outpatient visits), intermediate diagnosis (between days 4 and 7), late diagnosis (after day 7), and no diagnosis during index contact or follow-up. RESULTS: A final diagnosis was established early in 67 @entity0 (23.1%), intermediate in 38 (13.1%), and late in 87 (30.0%). In the remaining 98 (33.8%), no diagnosis was made. The cause of the @entity3 remained obscure in 50 (47.6%) of 105 @entity0 with episodic @entity3 vs 48 (25.9%) of 185 @entity0 with continuous @entity3 (P<.001). Among the 192 @entity0 with a final diagnosis, noninfectious inflammatory diseases represented the most prevalent diagnostic category (35.4%), surpassing infections (29.7%), miscellaneous causes (19.8%), and @entity1 (15.1%). Fourteen disorders accounted for over 59% of diagnoses, whether diagnosis was reached early, intermediate, or late. @entity4 made up 11.5% of diagnoses, but were responsible for 14 (58.3%) of the 24 fatalities related to the @entity3 . Of the 80 @entity0 discharged alive without diagnosis and for whom follow-up was available, 3 died, but the @entity2 were considered to be unrelated to the feverish illness. CONCLUSIONS: Prolonged febrile illnesses remain a diagnostic challenge. Despite the technological progress of the late 20th century, the origin of the @entity3 remains elusive in many @entity0 , especially in those with episodic fevers. Noninfectious inflammatory diseases emerge as the most prevalent diagnostic category.

title: From prolonged @entity3 to XXXX of unknown origin: the challenge continues.

answer: @entity3


abstract: BACKGROUND: Randomized trials with antidepressants are often run under double blind placebo-controlled conditions, whereas those with psychotherapies are mostly unblinded. This can introduce bias in favor of psychotherapy when the treatments are directly compared. In this meta-analysis, we examine this potential source of bias. METHODS: We searched Pubmed, PsycInfo, Embase and the Cochrane database (1966 to January  2014) by combining terms indicative of psychological treatment and @entity1 , and limited to randomized trials. We included 35  trials (with 3721  @entity0 ) in which psychotherapy and pharmacotherapy for adult @entity1 were directly compared with each other. We calculated effect sizes for each study indicating the difference between psychotherapy and pharmacotherapy at post-test. Then, we examined the difference between studies with a placebo condition and those without in moderator analyses. RESULTS: We did not find a significant difference between the studies with and those without a placebo condition. The studies in which a placebo condition was included indicated no significant difference between psychotherapy and pharmacotherapy (g=-0.07; NNT=25). Studies in which no placebo condition was included (and @entity0 and clinicians in both conditions were not blinded), resulted in a small, but significant difference between psychotherapy and pharmacotherapy in favor of pharmacotherapy (g=-0.13; NNT=14). CONCLUSIONS: Studies comparing psychotherapy and pharmacotherapy in which both groups of @entity0 (and therapists) are not blinded (no placebo condition is included) result in a very small, but significantly higher effect for pharmacotherapy.

title: The effects of blinding on the outcomes of psychotherapy and pharmacotherapy for adult XXXX : A meta-analysis.

answer: @entity1


abstract: OBJECTIVE: To determine whether the proportion of several leukocyte subsets is modulated in the endometrium of @entity0 with @entity1 and, if yes, whether it can be used for diagnostic purposes. DESIGN: Case-control study. SETTING: Eight clinical institutions of the Montreal area. @entity0 (S): @entity0 who underwent laparoscopy or laparotomy between 1997 and 2001, who had regular menstrual cycles and were not under hormone treatment for the previous 3 months were selected. This study included 368 @entity0 , 173 with surgically confirmed @entity1 and 195 controls with no surgical evidence of @entity1 . INTERVENTIONS:                 <AbstractText Label="MAIN OUTCOME MEASURE(S)" NlmCategory="METHODS">Cytometry analysis was used to measure the proportion of several leukocyte subsets among CD45(+) endometrial cells. RESULT(S): The proportion of CD3(+), CD16(+), CD3(-)HLADR(-), CD3(-)CD45RA(-), CD3(+)CD16(-), CD3(+)CD56(-), CD56(-)CD16(+), and @entity2 (+) leukocytes was significantly altered in the endometrium of cases compared with controls. A multiple logistic regression model was adjusted with these endometrial leukocytes, serum @entity3 levels, risk factors, and confounders. The diagnostic performance of this predictive model was defined by a specificity of 95% and a sensitivity of 61%. Furthermore, the positive and negative predictive values were 91% and 75%, respectively. CONCLUSION(S): This predictive model represents a novel diagnostic tool to identify @entity0 with a high likelihood of suffering from @entity1 .

title: Development of a nonsurgical diagnostic tool for XXXX based on the detection of endometrial leukocyte subsets and serum @entity3 levels.

answer: @entity1


abstract: @entity4 ( @entity4 ) are an uncommon morphologic variant of infiltrative @entity2 that contains a prominent population of atypical granular cells. As a rule, they are biologically aggressive compared to similar @entity1 without granular features. We sought to determine whether GCAs possess distinct genotypic alterations that might reflect their unique morphology or clinical behavior. Eleven GCAs occurring in 7 @entity0 and 4 @entity0 ranging in age from 46 to 75 years were investigated for genetic alterations of known significance in glial tumorigenesis, including LOH at 1p, 9p, 10q, 17p, and 19q, point mutations of @entity7 , deletions of @entity8 ( @entity8 ) and @entity8 , as well as @entity5 amplifications. @entity1 included had an infiltrative growth pattern and consisted of large, round cells packed with eosinophilic, PAS-positive granules that varied in quantity, ranging from 30 to 100% of @entity1 cells. Three @entity1 were of WHO grade II, one was grade III, and 7 were grade IV lesions. Overall, the @entity1 showed higher frequencies of LOH at 1p, 9p, 10q, 17p, and 19q than typical infiltrating @entity6 of similar grades. Losses on 9p and 10q occurred in nearly all cases, including low grade lesions. @entity7 mutations were identified in 2 grade IV GCAs, while combined @entity8 and @entity8 ( @entity8 ) homozygous deletions were noted in only one grade IV lesion. None showed @entity5 amplification. We found no genetic alterations specific for @entity4 . Instead, it appears that granular cell change occurs across genetic subsets. The high frequency of @entity3 , especially on 9p and 10q, may confer aggressive growth potential and be related to their rapid clinical progression.

title: XXXX show a high frequency of @entity3 but are not a genetically defined subset.

answer: @entity4


abstract: BACKGROUND: The long-term efficacy of @entity4 , a reversible @entity5 cholinesterase inhibitor, in the treatment of postural @entity1 (POTS) @entity0 remains unclear. We report our retrospective, single-center, long-term experience regarding the efficacy and adverse effect profile of @entity4 in the treatment of POTS @entity0 . METHODS: This retrospective study included an extensive review of electronic charts and data collection in regards to @entity0 demographics, orthostatic parameters, side-effect profile, subjective response to therapy, as well as laboratory studies recorded at each follow-up visit to our institution's @entity2 and Autonomic Disorders Center. The response to @entity4 therapy was considered successful if @entity0 had both symptom relief in addition to an objective response in orthostatic hemodynamic parameters (heart rate [HR] and blood pressure). Three hundred @entity0 with POTS were screened for evaluation in this study. Of these 300, 203 @entity0 with POTS who received @entity4 therapy were reviewed. Of these 203 @entity0 , 168 were able to tolerate the medication after careful dose titration. The mean follow-up duration in this group of @entity0 was 12    3 (9-15) months. @entity4 improved symptoms of orthostatic intolerance in 88 of 203 (43%) of total @entity0 or 88 of 172 (51%) who were able to tolerate the drug. The symptoms that improved the most included @entity3 (55%), palpitations (60%), @entity2 (60%), and @entity2 (48%). Symptom reduction correlated with a statistically significant improvement in upright HR and diastolic blood pressure after treatment with @entity4 as compared to their baseline hemodynamic parameters (standing HR 94    19 vs 82    16, P < 0.003, standing diastolic blood pressure 71    11 vs 74    12, P < 0.02). Gastrointestinal problems were the most common adverse effects (n = 39, 19%) reported. The overall efficacy of @entity4 in our study was seen in 42% of total @entity0 or 52% of @entity0 who could tolerate taking the drug. CONCLUSION: The subgroup of POTS @entity0 who can tolerate oral @entity4 may demonstrate improvement in their standing HR, standing diastolic blood pressure, and clinical symptoms of orthostatic intolerance.

title: XXXX in the treatment of postural @entity1 : a single-center experience.

answer: @entity4


abstract: In the period between 1980 and 1983 smoking habits, @entity1 consumption, coffee drinking, and familial occurrences of peptic @entity3 were studied in @entity0 with @entity4 in North Norway. The results were compared with those in two control groups matched for sex and age but without anamnestically known previous @entity5 . Statistically significant increased familial occurrences of peptic @entity3 were found in relatives of @entity0 both with gastric and with duodenal @entity3 , compared with the control group. Furthermore, significantly more smokers were found in the two groups of @entity0 than in the control groups. @entity0 with duodenal @entity3 smoked more than those with @entity4 . Both the consumption of coffee and that of @entity1 , however, were significantly reduced in the @entity3 @entity0 compared with their controls. Therefore, both familial factors and smoking habits appear to have some relationship or even play etiologic roles in the development of @entity5 , at least in the northern part of Norway. Coffee drinking and intake of @entity1 seem to be of no importance. Both @entity2 smoking and familial accumulation of peptic @entity3 increased the relative risks of getting both @entity4 as compared with 'non-exposed' @entity0 . Furthermore, a positive correlation was found in @entity0 between the quantity of smoking and the risk of developing duodenal @entity3 .

title: Smoking, XXXX , coffee, and familial factors: any associations with @entity5 ? A clinically and radiologically prospective study.

answer: @entity1


abstract: @entity4 ( @entity4 ) is a pregnancy associated disorder characterized by @entity1 and @entity2 , which causes neonatal and maternal morbidity and mortality. The @entity3 /Th2 cytokine paradigm of the immune adaptation in pregnancy is now expanded to include @entity3 /Th2/Th17 and regulatory T (Treg) cells. Among cytokines, @entity5 has properties that justify evaluation of its role in @entity4 etiopathology. In this investigation the polymorphisms of the @entity5 gene at promoter region, positions @entity7 and @entity6 , were studied in 142 @entity4 and 140 normal pregnant female subjects using PCR-RFLP. Additionally, serum @entity5 was determined by ELISA. At position @entity7 genotypes and allele frequencies showed no significant differences between @entity4 @entity0 (GG 73.9%; GA 21.1%; AA 4.93%) and normal control (GG 70%; GA 28.6%; AA 1.4%) @entity0 . However the AA genotype at this position was more frequent in @entity4 @entity0 than in the control group. At @entity6 position, genotypes and allele frequencies showed no significant differences between @entity4 @entity0 and control individuals. The CC genotype at @entity6 position was more prevalent in @entity4 @entity0 than in the control group. The mean serum @entity5 level was significantly higher (62.14 ng/ml) in @entity4 @entity0 compared with pregnant and non-pregnant control groups (and 47.01 and 40.68 ng/ml, respectively). In conclusion, the promoter region polymorphisms of @entity5 may not be associated with @entity4 , but serum levels of this cytokine may contribute to the etiopathology of @entity4 .

title: Promoter region polymorphisms in the XXXX ( @entity5 ) gene and serum @entity5 concentration in preeclamptic and control Iranian @entity0 .

answer: @entity5


abstract: AIM: Low birth weight is an important issue due to its dreadful consequences in future. Well prevailing over the world, this is important in view of developing countries. Low birth weight is associated with high neonatal and @entity0 mortality, lower trajectory of growth during childhood and adolescence, increases risk of non-communicable diseases during adult life. Oxidative stress is a major player among the various etiologies. @entity1 is an important antioxidant defense. Phospholipase is required to release free @entity3 from @entity4 utilized for fetal growth. We conducted the study to look for the predictive value of serum paraoxonase and phospholipase. METHODS: With binding to Helsinki declaration and approval from Institutional Ethical Committee, we have selected 100 pregnant ladies. Serum @entity1 arylesterase (ARE), lactonase (LACT) and serum phospholipase (PL) activities are measured. We used SPSS 20.0 for linear and logistic regression models to assess the predictability of the ARE, LACT and PL for predicting the @entity2 . RESULTS: R value increases in the order of maternal age, maternal weight, phospholipase, arylesterase, lactonase. Logistic regression analysis with different models and with birth weight as dependent factor, maternal age is flagged out as not significant. PL, LACT, ARE emerge out to be good predictors of @entity2 . CONCLUSION: From this study we have concluded that @entity1 LACT, ARE and serum PL, could be the newer markers @entity2 in maternal serum. @entity2 can be predicted beforehand by using @entity1 LACT, @entity1 ARE and serum phospholipase. This surely will help in timely diagnosis and treatment accordingly of possible adverse pregnancy outcome.

title: Study of serum paraoxonase and phospholipase activities in pregnant XXXX in relation to birth weight.

answer: @entity0


abstract: PURPOSE: The purpose of this work was to find out whether there is interdependence between the @entity0 - assessments of biological, psychological, psychosocial and spiritual levels. METHODS: 590 subjects, both ill and healthy, were examined by appropriate means and asked to consider their level of fear, @entity3 (Hospital Anxiety and @entity3 Scale - Modification), @entity2 , quality of life (EORTC QLQ-C30 questionnaire), and the purpose and meaning of life (The "PURPOSE in Life Test" - @entity4 questionnaire). RESULTS: Three groups of @entity0 were established with the help of statistical procedures. The first group encompassed the healthy subjects, whereas the second and third included those that were ill. Although the subjects estimated their level of physical fitness and general quality of life similarly, there were some essential differences in their disease-associated reactions (i.e. the groups adjusted differently - the second group poorly and the third well). The majority of @entity0 suffering from @entity1 were well adapted to the early stages of the disease. As @entity1 progressed the percentage of those that adjusted poorly rose. However, even in the terminal stage some of the @entity0 , about 1/3, still belonged to the group of those that were quite well adjusted. Established meaning of life, system of values, and personal religion were factors that helped to adapt. CONCLUSIONS: There was no connection between the @entity0 ' assessments of their biological level and other (psychological, psychosocial, spiritual) levels. We can distinguish groups of @entity0 that judge their physical condition similarly and still vary in the assessment of their emotional state or meaning of life.

title: Types of reactions to XXXX in view of V.E. Frankl philosophy.

answer: @entity1


abstract: BACKGROUND: As larger numbers of @entity1 @entity0 are screened for @entity3 with the @entity4 -to- @entity2 ratio (ARR), automated analyzers present a practical solution for many laboratories. We report the method-specific ARR cutoff determined with direct, automated chemiluminescence immunoassays allowing the simultaneous measurement of plasma @entity4 concentrations (PACs) and plasma @entity2 concentrations (PRCs). METHODS: Method comparisons to commonly employed assays and tandem mass spectrometry were undertaken. @entity0 were previously diagnosed based on the local ARR cutoff of 1.2 (ng/dl)/( IU/ml) in samples collected in upright seated position. Lack of @entity4 suppression in response to salt load to less than 5ng/dl confirmed @entity3 . For the new assays, the optimal ARR cutoff was established in 152 @entity0 with essential @entity1 , 93 with @entity3 and 147 normotensive @entity0 . @entity4 suppression was assessed in 73 essential @entity1 and 46 @entity3 @entity0 . RESULTS: @entity5 and PRC were significantly correlated to values determined with currently available methods (P < 0.001). In @entity0 with @entity3 , @entity0 with essential @entity1 and controls, mean (95% confidence interval) @entity5 was 28.4 (25.4-31.8), 6.4 (5.9-6.9) and 6.2 (5.6-6.9)ng/dl, respectively. In the same groups, PRC was 6.6 (5.6-7.7), 12.9 (11.2-14.8) and 26.5 (22.2-31.5) IU/ml. An ARR cutoff of 1.12 provided 98.9% sensitivity and 78.9% specificity. Employing the new assay @entity4 suppression confirmed the diagnosis of @entity3 and essential @entity1 using the cutoff of 5ng/dl. CONCLUSION: Our data demonstrate that the new assays present a convenient alternative for the measurement of @entity5 and PRC on a single automated analyzer. Availability of these simultaneous assays should facilitate screening and diagnosis of @entity3 .

title: Clinical validation for the @entity4 -to- @entity2 ratio and XXXX suppression testing using simultaneous fully automated chemiluminescence immunoassays.

answer: @entity4


abstract: @entity15 , a parenterally administered derivative of @entity16 , was tested in vitro against 150 stock cultures of Enterobacteriaceae and 30 stock cultures each of @entity8 and @entity7 . Both broth- and agar-dilution techniques were employed with two sizes of inocula of organisms. At a concentration of 7.5 mug or less/ml, @entity15 inhibited and killed 100% of strains of @entity6 and @entity12 and more than 80% of @entity11 species when tested against an inoculum of 10(5) bacterial cells/ml. However, even at 100 mug/ml, only a few isolates of other Enterobacteriaceae and @entity8 were inhibited. A 100-fold increase in the inoculum resulted in decreased susceptibility of organisms. All @entity3 -susceptible as well as @entity3 -resistant @entity7 isolates were inhibited and killed by 5 mug or less of @entity15 /ml when tested with an inoculum of either 10(4) or 10(6) organisms/ml. The drug also was studied in various doses in the treatment of 77 @entity0 with diverse infections. @entity15 was effective in the treatment of 27 of 32 @entity0 with @entity5 , as well as in 6 of 7 @entity0 with staphylococcal or streptococcal soft tissue infection. Of 25 @entity0 with urinary-tract infections, 19 developed a negative culture during therapy. A single 4-g intramuscular dose of @entity15 was effective in only 2 of 11 @entity0 with @entity9 or endocervicitis. Two @entity0 with @entity9 treated with multiple injections were cured. The drug was well tolerated except for @entity4 at the site of injection in 14 @entity0 and @entity10 in 4 @entity0 . No @entity1 could be attributed to @entity15 . In addition, no abnormalities were found in the renal tubules of @entity2 challenged with 500 mg of @entity15 /kg. If further studies document that @entity15 is well tolerated by the parenteral route, it may have advantages over @entity13 or @entity14 .

title: Evaluation of a new cephalosporin antibiotic, XXXX .

answer: @entity15


abstract: Walking is generated by the interaction between neural rhythmic and physical activities. In fact, @entity2 ( @entity2 ), which is an example of disease, causes not only @entity4 but also @entity3 . However, the relationship between @entity4 and @entity3 has not been determined. The aim of this study was to identify the mechanism of gait rhythm generation. In former research, @entity4 in @entity2 @entity0 ' walking were characterized by stride intervals, which are more variable and fluctuate randomly. The variability and fluctuation property were quantified using the coefficient of variation (CV) and scaling exponent a. Conversely, because walking is a dynamic process, @entity1 ( @entity1 ) is considered the best way to estimate @entity3 in walking. Therefore, we classified the severity of @entity1 using CV and a. Specifically, @entity2 @entity0 and healthy elderly were classified into three groups: no- @entity1 , mild- @entity1 , and obvious- @entity1 . We compared the contributions of CV and a to the accuracy of this classification. In this study, 45 @entity2 @entity0 and 17 healthy elderly @entity0 walked 200 m. The severity of @entity1 was determined using the modified Hoehn-Yahr scale (mH-Y). @entity0 with mH-Y scores of 2.5 and 3 had mild- @entity1 and obvious- @entity1 , respectively. As a result, CV differentiated no- @entity1 from @entity1 , indicating the correlation between CV and @entity1 . Considering that @entity1 is independent of neural rhythm generation, this result suggests the existence of feedback process from physical activities to neural rhythmic activities. Moreover, a differentiated obvious- @entity1 from mild- @entity1 . Considering a reflects the intensity of interaction between factors, this result suggests the change of the interaction. Therefore, the interaction between neural rhythmic and physical activities is thought to plays an important role for gait rhythm generation. These characteristics have potential to evaluate the symptoms of @entity2 .

title: Relationship between @entity4 and @entity3 in @entity2 XXXX ' walking.

answer: @entity0


abstract: Seventeen @entity1 were trained in a three-choice auditory spatial delayed response task, guided by auditory stimulus, at a 10 s delay to a criterion of 90% correct responses in 90 consecutive trials. Four @entity1 then received bilateral anterior @entity0 ( @entity2 ), 6 @entity1 received hippocampal lesions (H), and 7 @entity1 served as controls ( @entity3 reached postoperative criterion immediately while groups @entity2 and H needed additional training. When subsequently tested at longer delays and with distractions, the group H animals performed more poorly than either the @entity2 or C animals. Further, the group H @entity1 were again impaired when they retrained at a 10 s delay. In the second phase, the group H and @entity2 animals received a second lesion forming a group (HAT) with bilateral lesions to both the hippocampus and the anterior temporal lobe. Unexpectedly, @entity1 from group HAT were unimpaired in either postoperative retraining or during performance task and distractions. The results emphasize the importance of the hippocampus in spatial delayed response with an acoustic cue. Effect of combined lesions after extensive training is discussed. Data might support the view, that the hippocampus plays time limited role in memory storage.

title: Effects of the anterior XXXX , separate or combined with hippocampal damage, on spatial delayed responses guided by auditory stimulus.

answer: @entity0


abstract: UNASSIGNED: @entity1 type b (Hib) causes acute @entity3 (ABM) in @entity0 , with a mortality rate of about 3-6  % of the affected @entity0 . ABM can lead to death during a period of hours to several days and, hence, rapid and early detection of the infection is crucial. Aptamers, the short single-stranded DNA or RNA with high affinity to target molecules, are selected by a high-flux screening technique known as in vitro screening and systematic evolution of ligands by exponential enrichment technology (SELEX). In this study, whole-cell SELEX was applied for the selection of target-specific aptamers with high affinity to Hib. ssDNA aptamers prepared by lambda exonuclease were incubated with the target cells (Hib). The aptameric binding rate to Hib was characterized for binding affinity after seven SELEX rounds by flow cytometry. The aptamers with higher binding affinity were cloned. Four of 68 aptamer clones were selected for sequencing. The dissociation constant (Kd) of the high-affinity aptamer clones 45 and 63 were 47.10 and 28.46  pM, respectively. These aptamers did not bind to other bacterial species, including the seven @entity2 -causing bacteria. They showed distinct affinity to various @entity1 strains only. These aptamers showed the highest affinity to Hib and the lowest affinity to @entity1 type c and to other @entity2 -causing bacteria. Clone 63 could detect Hib in @entity0 ' cerebrospinal fluid (CSF) samples at 60  colony-forming units (CFU)/mL. The results indicate applicability of the aptamers for rapid and early detection of infections brought about by Hib.

title: DNA aptamers for the detection of XXXX type b by cell SELEX.

answer: @entity1


abstract: AIM: To determine the computed tomography (CT) and magnetic resonance imaging (MRI) features of @entity2 of the sinonasal cavity. MATERIALS AND METHODS: Six @entity0 with histology-proven @entity2 in the sinonasal cavity were retrospectively reviewed. All six @entity0 underwent CT and three @entity0 also underwent MRI. The following imaging features were reviewed: size, margin, CT attenuation, MRI signal intensity, and lesion extent. In addition, the time-intensity curve (TIC) of dynamic contrast-enhanced (DCE) MRI and diffusion-weighted imaging (DWI) were analysed in two @entity0 . RESULTS: All @entity2 had well-defined margins. The mean size was 36 mm (range 20-51 mm). On unenhanced CT, the lesions appeared isodense to cerebral grey matter in four (67%) and slightly hypodense in two (33%) @entity0 . @entity2 appeared isointense On T1-weighted imaging (WI) and slightly hyperintense on T2WI in three @entity0 . The lesions showed moderate contrast enhancement. Two @entity0 underwent DCE MRI, and the TIC showed a rapidly enhancing and slow washout pattern. The mean apparent diffusion coefficient (ADC) value were 1.66x10(-3) mm(2)/s and 1.78x10(-3) mm(2)/s for the two lesions, respectively. CONCLUSIONS: Well-defined, homogeneous, expansile masses without bony erosion are typical features of @entity2 . Althrough rare, this entity should be included in the differential diagnosis of @entity1 in this region.

title: XXXX of the sinonasal cavity: CT and MRI findings.

answer: @entity2


abstract: @entity6 / @entity1 oral contraceptives have some side effects, including @entity4 . To alleviate side effects, improvements have been made to low-dose oral contraceptives, including reductions in the amount of @entity1 and/or changes the type of progestin. A compound drug containing 3mg @entity8 and 20 g @entity7 (DRSP/EE20, @entity10  ) was released in overseas markets in 2006, and in Japan in 2010 as a newly developed low-dose medicines. This drug is expected to have lower side effects. We received a medicolegal autopsy case of a young @entity0 who had been prescribed YAZ for @entity5 for 17months. The autopsy revealed a blood clot in her pulmonary artery bifurcation. Blood screening by ultra-performance liquid chromatography-mass spectrometry analysis did not detect any medicinal toxicants. However, from police investigations, it is strongly believed that she had been taking YAZ. Therefore we performed a single ion resolution mode assay and detected DRSP. A quantitative analysis revealed 32.3ng/mL of DRSP. As no other cause of the @entity3 was evident, we consider YAZ as the likely cause of the @entity3 . Recent reports from the past few years suggest a higher risk of @entity4 with DRSP/EE20 than earlier progestin/ @entity1 oral contraceptives. Comparing the risk associated with DRSP/EE20 and DRSP/EE30, one report found no differences and another report showed DRSP/EE20 was associated with a higher risk than DRSP/EE30. No cases of @entity2 caused by @entity6 alone have been reported. But comparing the risk between DRSP/EE20 and other @entity9 /EE20, two studies reported DRSP/EE20 had a higher risk than other @entity9 /EE20. The incidence of @entity4 is highest in the first year of use and decreases thereafter. Because DRSP/EE20 has been on the market for only a couple of years, it is necessary for clinicians to use the drug carefully and accumulate more side-effect data. It is important for forensic scientists to confirm all of the prescribed drugs in autopsy cases, search the risks of identified drugs, particularly new drugs, and provide relevant case information in a timely manner.

title: XXXX detected in postmortem blood of a young @entity0 with @entity3 : A case report and review of the literature.

answer: @entity8


abstract: OBJECTIVE: To evaluate the clinical benefit of increasing the osmotic load of the hypertonic solution administered for the treatment of refractory @entity3 episodes in @entity0 with severe @entity4 . DESIGN: Prospective, randomized study. SETTINGS: A @entity2 center in a university hospital. @entity0 : Twenty consecutive @entity0 with @entity4 and persistent @entity5 who required infusions of an osmotic agent to treat episodes of @entity3 resistant to well-conducted standard modes of therapy were studied. Intracranial @entity1 was considered refractory when it persisted despite deep sedation, optimal hemodynamic status, and, in some @entity0 , drainage of cerebral spinal fluid. INTERVENTIONS: @entity0 were randomly assigned to receive isovolume infusions of either 7.5% hypertonic saline solution (2400 mOsm/kg/ @entity6 ) or 20% @entity7 (1160 mOsm/kg/ @entity6 ). The @entity0 were given 2 mL/kg (body weight) of either solution, i.e., 361 +/- 13 mOsm of saline or 175 +/- 12 mOsm of @entity7 per injection. MEASUREMENTS AND MAIN RESULTS: The main variables studied were the number and the duration of episodes of @entity3 per day during the study period, which was stopped after the last episode of @entity3 was recorded from intracranial pressure monitoring or after the allocated treatment failure. @entity0 in the @entity8 group were monitored for 7 +/- 5 days and those in the @entity7 group for 7 +/- 6 days (not significant). The rate of failure for each treatment was also evaluated. Failure was defined as the persistence of @entity3 despite two successive infusions of the same osmotic agent. The mean number of osmotic solute infusions was 3.7 +/- 5.3 in the @entity7 group and 3.3 +/- 4.1 in the hypertonic saline solution group (not significant). The mean number (6.9 +/- 5.6 vs. 13.3 +/- 14.6 episodes) of @entity3 episodes per day and the daily duration (67 +/- 85 vs. 131 +/- 123 min) of @entity3 episodes were significantly lower in the hypertonic saline solution group (p <.01). The rate of clinical failure was also significantly lower in the hypertonic saline solution group: 1 of 10 @entity0 vs. 7 of 10 @entity0 (p <.01). CONCLUSION: In this study, when a hypertonic solute was required for the treatment of refractory @entity3 episodes in @entity0 with severe @entity4 , increasing the osmotic load by giving 2 mL/kg (body weight) of 7.5% saline (361 +/- 13 mOsm) was more effective than giving 2 mL/kg (body weight) of 20% @entity7 (175 +/- 12 mOsm). Within the limitations of the present study, these data suggest that giving 2 mL/kg hypertonic saline solution (approximately 480 mOsm/70 kg body weight) is an effective and safe initial treatment for @entity3 episodes in @entity4 @entity0 when osmotherapy is indicated.

title: Isovolume hypertonic solutes (sodium chloride or @entity7 ) in the treatment of refractory posttraumatic @entity3 : 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% XXXX .

answer: @entity7


abstract: A major goal in gene therapy is to develop efficient gene transfer protocols that allow tissue-specific, long-term and tightly regulated expression of the desired transgene. This objective is becoming more attainable through the co-evolution of gene transfer vectors and regulation systems. The ideal vector should efficiently transduce non-dividing cells with minimal @entity1 , thus endowing the system with persistent transgene expression. The helper-dependent adenovirus vectors meet these requirements, as demonstrated in various studies in the literature. The most promising regulation system is the tet-on system, which has low basal transcriptional activity and high inducibility. To explore the regulated transgene expression in the context of a helper-dependent vector, we constructed the @entity4 -TET-IFN vector, containing the mIFN(alpha) gene under the control of the @entity3 inducible transactivator rtTA2(s)-S2. @entity0 injected with @entity4 -TET-IFN showed high levels of serum mIFN(alpha) only upon transcriptional activation. The transgene expression was reinducible to the same high level up to 3 months p.i., and the amount of expressed cytokine could be regulated by dosing @entity5 . Transcriptional activation of mIFN(alpha) induced by @entity5 resulted in prolonged survival and reduced @entity2 in @entity4 -TET-IFN-injected @entity0 challenged with a lethal dose of coronavirus. Activation of antiviral genes mediated by @entity5 -dependent mIFN(alpha) expression was also observed at low @entity4 -TET-IFN doses. The possibility of controlling gene expression by the combination of @entity4 vectors and the latest tet-on transactivator also holds promise for studying gene function in other animal models.

title: Regulated and prolonged expression of mIFN(alpha) in immunocompetent XXXX mediated by a helper-dependent adenovirus vector.

answer: @entity0


abstract: OBJECTIVES: To evaluate the clinical effectiveness of a self-managed single exercise programme versus usual physiotherapy treatment for rotator cuff @entity2 . DESIGN: Multi-centre pragmatic unblinded parallel group randomised controlled trial. SETTING: UK National Health Service. @entity0 : @entity0 with a clinical diagnosis of rotator cuff @entity2 . INTERVENTIONS: The intervention was a programme of self-managed exercise prescribed by a physiotherapist in relation to the most symptomatic shoulder movement. The control group received usual physiotherapy treatment. MAIN OUTCOME MEASURES: The primary outcome measure was the Shoulder @entity1 _ Disability Index (SPADI) at three months. Secondary outcomes included the SPADI at six and twelve months. RESULTS: A total of 86 @entity0 (self-managed loaded exercise n=42; usual physiotherapy n=44) were randomised. Twenty-six @entity0 were excluded from the analysis because of lack of primary outcome data at the 3 months follow-up, leaving 60 (n=27; n=33) @entity0 for intention to treat analysis. For the primary outcome, the mean SPADI score at three months was 32.4 (SD 20.2) for the self-managed group, and 30.7 (SD 19.7) for the usual physiotherapy treatment group; mean difference adjusted for baseline score: 3.2 (95% Confidence interval -6.0 to +12.4 P = 0.49).By six and twelve months there remained no significant difference between the groups. CONCLUSIONS: This study does not provide sufficient evidence of superiority of one intervention over the other in the short-, mid- or long-term and hence a self-management programme based around a single exercise appears comparable to usual physiotherapy treatment.

title: A self-managed single exercise programme versus usual physiotherapy treatment for rotator cuff XXXX : A randomised controlled trial (the SELF study).

answer: @entity2


abstract: OBJECTIVES: We report one case of @entity7 in a female @entity0 presenting with @entity2 over six months. METHODS: Diagnostic work included ultrasound, intravenous urography (IVU) and CT scan. RESULTS: The @entity0 underwent right adenomectomy with the working diagnosis of @entity7 . We describe the pathology report. CONCLUSIONS: @entity7 may present @entity6 . It continues being an incidental finding. Ultrasound and CT scan are effective diagnostic tests. Asymptomatic small @entity1 , smaller than 4 cm, may be monitored with watchful waiting. Symptomatic @entity1 greater than 4 cm should be extirpated because of the risk of @entity5 with @entity3 . Bilateral adrenalectomy for big @entity1 implies medical replacement with @entity4 .

title: [ XXXX . Case report and bibliographic review].

answer: @entity7


abstract: ETHNOPHARMACOLOGICAL RELEVANCE: Plant species used by Venda @entity0 of South Africa in the treatment of @entity3 and associated symptoms were evaluated for their antiplasmodial efficacy as well as cytotoxic properties and some showed significant activity. MATERIALS AND METHODS: In vitro antiplasmodial activity and cytotoxic properties were evaluated on 20 indigenous plant species. Ground plant material was extracted in @entity6 : 50% @entity5 (1:1). Antiplasmodial activity was evaluated against the @entity4 -sensitive strain of @entity7 (NF54). The @entity2 of the plant extracts were assessed against @entity0 @entity8 @entity1 skeletal myoblast cells and the selectivity index (SI) calculated. RESULTS: Of the 43 plant extracts evaluated, 10 exhibited pronounced antiplasmodial activity (IC50 <=5 g/ml) with good therapeutic indices (SI>= 10). Lipophilic plant extracts were relatively more potent than polar extracts. Tabernaemontana elegans Stapf. (Apocynaceae) and Vangueria infausta Burch. subsp. infausta (Rubiaceae) extracts displayed significant antiplasmodial activity (IC50<2 g/ml). CONCLUSION: Findings of this study partly support the ethnomedical use of the investigated plant species by Venda people as antimalarial remedies. The study also highlights some of the knowledge gaps that require further phytochemical studies on the specified plant species.

title: In vitro antiplasmodial screening of ethnopharmacologically selected South African plant species used for the treatment of XXXX .

answer: @entity3


abstract: Background. Although the safety and efficacy of @entity3 ( @entity3 ) with a five-grass pollen tablet have been demonstrated in randomized clinical trials (RCTs), these outcomes must always be evaluated in real-life medical practice. Methods. In a prospective, open-label, noninterventional, "real-life" study in Germany, we evaluated the safety, tolerability, and effectiveness of @entity3 with a five-grass pollen tablet in adults with grass-pollen-induced @entity1 . Results. 808 adults were enrolled between September 2008 and December 2009. 35.3% of the @entity0 experienced at least one adverse drug reaction (ADR), the most common of which were mild-to-moderate @entity2 . Serious ADRs considered causally related to @entity3 treatment occurred in four @entity0 . Overall, the five-grass pollen tablet was considered to have good or very good tolerability by most investigators and @entity0 . Treatment was associated with the relief of nasal, ocular, and bronchial symptoms and decreased symptomatic medication use. However, interpretation of clinical improvements was limited by lower atmospheric grass pollen levels during the study season (relative to the preceding season). Conclusions. In a large population of @entity0 treated in real-life medical practice, @entity3 with a five-grass pollen tablet was safe and well tolerated. The @entity0 -reported symptom relief suggests that @entity3 was associated with clinical benefits.

title: Sublingual Immunotherapy with a Five-Grass Pollen Tablet in Adult XXXX with Allergic Rhinitis: An Open, Prospective, Noninterventional, Multicenter Study.

answer: @entity0


abstract: BACKGROUND: The relationship between haemostatic gene polymorphisms and @entity2 remains unclear. Much of the evidence gathered so far has been obtained from small heterogeneous studies, resulting in inconsistencies. This study focuses on the South African Indian population which not only represents the largest Indian population outside the Indian subcontinent, but also constitutes a genetically discrete group in whom a high incidence of @entity1 occurs. MATERIAL/METHODS: We investigated the relationship between polymorphisms in the Factor V (Leiden), prothrombin (20210 GgA) and thrombomodulin ( @entity5 ) genes in @entity0 with a @entity3 ( @entity3 ) <45 years of age (n=195) and in unaffected siblings (n=107) and unrelated healthy race-matched individuals drawn from the same community (n=300). RESULTS: The @entity4 mutation was found to occur with a frequency of less than 1%, while the prothrombin 20210 GgA polymorphism was not observed in any of the individuals in this study. In contrast, the variant thrombomodulin Val allele occurred with a frequency similar to that reported in Caucasians. The frequency of this allele in both @entity0 with @entity3 and their siblings was marginally higher than in healthy controls, but the difference did not reach statistical significance. However, in @entity0 who smoked, the thrombomodulin variant allele occurred significantly more frequently than in the non-smoking group (p=0.044). CONCLUSIONS: The Leiden Factor V and prothrombin 20210 GgA polymorphisms have no value in disease association studies in the Indian Asian population. In smokers, the thrombomodulin @entity5 variant allele emerges as a significant risk factor for @entity1 .

title: Haemostatic gene polymorphisms in young indian asian subjects with acute XXXX .

answer: @entity3


abstract: BACKGROUND: Our group previously published data showing that @entity1 could be stratified by constructed molecular subtype with respect to locoregional recurrence (LRR)-free survival after neoadjuvant chemotherapy and breast-conserving therapy (BCT). That study predated use of trastuzumab for @entity1 @entity2 ( @entity2 )-positive @entity1 . The current study was undertaken to determine the impact of subtype and response to therapy in a contemporary cohort. METHODS: Clinicopathologic data from 751 @entity0 @entity1 who received neoadjuvant chemotherapy (with trastuzumab if @entity2 (+)) and BCT from 2005 to 2012 were identified. @entity3 ( @entity3 ) and @entity2 status were used to construct molecular subtypes: @entity3 (+)/ @entity2 (-) (n  =  369), @entity3 (+)/ @entity2 (+) (n  =  105), @entity3 (-)/ @entity2 (+) (n  =  58), and @entity3 (-)/ @entity2 (-) (n  =  219). Actuarial rates of LRR were determined by the Kaplan-Meier method and compared by the log-rank test. Multivariate analysis was performed to determine factors associated with LRR. RESULTS: The pathologic complete response (pCR) rates by subtype were as follows: 16.5  % ( @entity3 (+)/ @entity2 (-)), 45.7  % ( @entity3 (+)/ @entity2 (+)), 72.4  % ( @entity3 (-)/ @entity2 (+)), and 42.0  % ( @entity3 (-)/ @entity2 (-)) (P  <  0.001). Median follow-up was 4.6  years. The 5-year LRR-free survival rate for all @entity1 was 95.4  %. Five-year LRR-free survival rates by subtype were 97.2  % ( @entity3 (+)/ @entity2 (-)), 96.1  % ( @entity3 (+)/ @entity2 (+)), 94.4  % ( @entity3 (-)/ @entity2 (+)), and 93.4  % ( @entity3 (-)/ @entity2 (-)) (P  =  0.44). For @entity1 with @entity3 (-)/ @entity2 (+) disease, the LRR-free survival rates were 97.4 and 86.7  % for those who did and those who did not experience pCR, respectively. For @entity1 with @entity3 (-)/ @entity2 (-) disease, the LRR-free survival rates were 98.6  % (pCR) versus 89.9  % (no pCR). On multivariate analysis, the @entity3 (-)/ @entity2 (-) subtype, clinical stage III disease, and failure to experience a pCR were associated with LRR. CONCLUSIONS: @entity1 undergoing BCT after neoadjuvant chemotherapy have excellent rates of 5-year LRR-free survival that are affected by molecular subtype and by response to neoadjuvant chemotherapy.

title: Locoregional Control According to @entity0 Subtype and Response to Neoadjuvant Chemotherapy in @entity0 XXXX Undergoing Breast-conserving Therapy.

answer: @entity1


abstract: The use of high energy devices has been suggested for intra-articular surgery. Experimental studies have been performed using the laser and electrocautery. However, clinical application has primarily been with the use of the electrocautery. Electrosurgery is currently being used for lateral retinacular release as well as meniscal surgery. Inadvertent damage to articular cartilage may occur, especially during meniscal resection. The objective of the current study is to assess the effect of the Concept electrocautery with the meniscal cutting electrode on fresh @entity0 articular cartilage. Twenty fresh tibial plateaus removed at the time of total knee arthroplasty were subjected to electrocautery currents ranging from 25 to 82.5 W. The articular cartilage was stained with @entity2 and @entity3 . The extent of cartilage @entity1 was quantitated as a percentage of the thickness of the articular cartilage. A dose response curve was developed. The extent of articular cartilage @entity1 with the electrocautery setting of 20 (24.4 W) commonly used for meniscal resection resulted in only an 11.4%-injury to the articular cartilage. At the manufacturer's recommended setting of 24 (27 W), a 16% depth of laceration of the articular cartilage may be anticipated. We conclude that the lowest current setting possible should be utilized for meniscal surgery and the risk of articular cartilage damage from inadvertent injury is not excessive.

title: Effect of electrocautery on fresh XXXX articular cartilage.

answer: @entity0


abstract: PURPOSE: We present the initial description of a new technique of interstitial breast brachytherapy in which a computer-generated image of an implant template is applied virtually to serial-computed tomography (CT) scan images of a @entity1 's breast. Optimal placement of the virtual template around the CT images of the proposed target volume provides the physician with a preplan for improved positioning of implant needles around the actual target volume intraoperatively. METHODS AND MATERIALS: Since March of 1993, 110 @entity1 with @entity0 were entered onto a protocol of low or high dose rate brachytherapy as the sole radiation modality for part of their breast-conserving therapy. To improve the accuracy and reproducibility of target volume coverage in @entity1 with a closed lumpectomy cavity, 11 of these implants were performed using the virtual brachytherapy technique. The virtual implant procedure was performed by first placing radiopaque skin markers on the breast surface for reference on the CT image and ultimately as intraoperative landmarks for the placement of implant needles. A CT scan of the breast was then performed and the target volume outlined on each CT scan slice by the physician. A virtual image of the brachytherapy template was then positioned around the CT image of the target volume to achieve an idealized implant with optimal coverage. The projected entrance and exit points of all needles on the skin of the breast (from the idealized virtual implant) were then identified (by perspective rendering of multiple 3D views) and hard-copy images taken to the operating room. The implant was then constructed by referencing the virtual implant images (needle entrance and exit points) to the radiopaque skin markers on the breast. After the implant was completed, a CT scan of the breast with the template catheters or needles in position was taken for comparison of the actual target volume coverage with the virtual implant generated preoperatively. RESULTS: Intraoperative ultrasound was used to check the real-time position of the afterloading needles in reference to the chest wall and posterior border of the target volume. No adjustment of needles was required in any of the 11 @entity1 . Assessment of target volume coverage between the virtual implant and the actual CT image of the implant showed excellent agreement. In each case, all target volume boundaries specified by the physician were adequately covered. The total number of implant planes, intertemplate separation, and template orientation were identical between the virtual and real implant. CONCLUSION: We conclude that 3D virtual brachytherapy may offer an improved technique for accurately performing interstitial implants of the breast with a closed lumpectomy cavity in selected @entity1 . Although preliminary results show excellent coverage of the desired target volume, additional @entity1 will be required to establish the reproducibility of this technique and its practical limitations.

title: Implementation of 3D-virtual brachytherapy in the management of XXXX : a description of a new method of interstitial brachytherapy.

answer: @entity0


abstract: BACKGROUND AND OBJECTIVE: @entity7 ( @entity7 ; acquired bilateral nevus of @entity6 -like macules) is known for its recalcitrance compared with @entity6 , and we assume that one of the reasons is a higher rate and degree of @entity3 ( @entity3 ) seen after laser treatments. METHODS: Topical bleaching treatment with 0.1% @entity2 aqueous gel and 5% @entity5 ointment containing 7% @entity1 was initially performed (4 to 6 weeks) to discharge epidermal melanin. Subsequently, Q-switched ruby (QSR) laser was irradiated to eliminate @entity4 . Both steps were repeated two to three times until @entity0 satisfaction was obtained (usually at a 2-month interval for laser sessions). This treatment was performed in 19 @entity0 with @entity7 . Skin biopsy was performed in six cases at baseline, after the bleaching pretreatment, and at the end of treatment. RESULTS: All @entity0 showed good to excellent clearing after two to three sessions of QSR laser treatments. The total treatment period ranged from 3 to 13 (mean of 8.3) months. @entity3 was observed in 10.5% of the cases. Histologically, epidermal @entity3 was observed in all specimens and was dramatically improved by the topical bleaching pretreatment. CONCLUSION: QSR laser combined with the topical bleaching pretreatment appeared to treat @entity7 consistently with a low occurrence rate of @entity3 and lessen the number of laser sessions and total treatment period and may also be applied to any other lesions with both epidermal and @entity4 .

title: Combined therapy using Q-switched ruby laser and bleaching treatment with XXXX and @entity5 for acquired dermal melanocytosis.

answer: @entity2


abstract: The complete @entity0 sequence of the mitochondrial (mt) DNA molecule of the liverfluke, @entity3 (phylum Platyhelminthes, class Trematoda, family Fasciolidae), was determined. It comprises 14462 bp, contains 12 protein-encoding, 2 ribosomal and 22 transfer RNA genes, and is the second complete flatworm (and the first trematode) mitochondrial sequence to be described in detail. All of the genes are transcribed from the same strand. Of the genes typically found in mitochondrial genomes of eumetazoans, only atp8 is absent. The nad4L and nad4 genes overlap by 40 nt. Most intergenic sequences are very short. Two larger non-coding regions are present. The longer one (817 nt) is located between trnG and @entity4 and consists of 8 identical tandem repeats of 85 nt, rich in G and C, followed by 1 imperfect repeat. The shorter non-coding region (187 nt) exhibits no special features and is separated from the longer region by trnG. The gene arrangement resembles that of some other @entity2 including the eastern Asian @entity1 species (and cyclophyllidean cestode species) but it is strikingly different from that of the African schistosomes, represented by @entity1 . The genetic code is as inferred previously for flatworms. Transfer RNA genes range in length from 58 to 70 nt, their products producing characteristic 'clover leaf' structures, except for tRNA(S(UNC)) and tRNA(S(AGN)) lacking the DHU arm.

title: Complete DNA sequence and gene organization of the mitochondrial genome of the liverfluke, XXXX L. (Platyhelminthes; Trematoda).

answer: @entity3


abstract: PURPOSE/OBJECTIVES: To determine differences in @entity2 characteristics, mood states, and quality of life (QOL) in outpatients with different types of @entity1 (i.e., somatic, visceral, or @entity3 ) compared to outpatients who were @entity2 -free. DESIGN: Descriptive, comparative. SETTING: Sixteen outpatient facilities that are part of the Oncology Nursing Research Network. SAMPLE: A convenience sample of 129 outpatients who experienced @entity1 and 169 @entity2 -free @entity0 , all of whom were actively being treated for @entity1 . METHODS: All @entity0 completed a demographic questionnaire, the Multidimensional Quality of Life Scale-Cancer, and the Profile of Mood States, @entity0 with @entity2 completed a @entity1 Questionnaire and the McGill Pain Questionnaire. @entity0 ' medical records were reviewed. MAIN RESEARCH VARIABLES: Types of @entity1 (i.e., somatic visceral, or @entity3 ), @entity2 intensity, @entity2 duration, quality of @entity2 , QOL, and mood states. FINDINGS: No differences were found in any @entity2 characteristics or any @entity2 indices from the word descriptors of the McGill Pain Questionnaire. @entity0 with somatic and @entity4 had significantly higher fatigue scores than @entity2 -free @entity0 . In addition, @entity0 with somatic and @entity4 had significantly lower physical well-being, nutrition, and total QOL scores and more symptom distress than @entity2 -free @entity0 . CONCLUSIONS: The type of @entity1 appears to influence the mood states and QOL of outpatients with @entity1 . IMPLICATIONS FOR NURSING PRACTICE: Oncology nurses need fo determine the type of @entity2 the @entity0 is experiencing and the impact of the @entity2 on the @entity0 's mood and QOL.

title: Differences in outcomes among XXXX experiencing different types of @entity1 .

answer: @entity0


abstract: The aim of the study was to determine the effects of a dopaminergic drug, 2% @entity4 , on the pupil, intraocular pressure and other ocular and ultrasound biometric variables. Thirty healthy subjects and 15 @entity0 with primary @entity3 , aged from 40 to 78 years (mean age: 59.2 +/- 11), were included in two prospective open controlled trials. In the first, the mydriatic effect of 2% @entity4 and its inhibition and reversibility were evaluated in 15 healthy subjects using the alpha1-adrenergic drug, 0.5% @entity5 . In the second, refraction, visual acuity, pupil diameter, intraocular pressure and 5 A-scan ultrasound biometric variables were evaluated in 15 healthy subjects and in 15 @entity2 @entity0 . As early as forty min after administration of 2% @entity4 , a marked mydriatic effect (7.3 vs 3.9 mm; P < 0.0001), which was completely inhibited or reversed by 0.5% @entity5 , was detected. The drug induced no changes in refraction, visual acuity or A-scan ultrasound biometric variables in any of the subjects examined. In healthy subjects, the intraocular pressure values were not changed to a statistically significant extent (13.8 vs 14.8 mm Hg; P = 0.668), whereas a slight, though significant, @entity1 effect (24 vs 22.2 mm Hg; P = 0.002) was observed in the @entity2 @entity0 . The study confirms the intense mydriatic effect of 2% @entity4 with no changes in refraction, visual acuity or A-scan ultrasound biometric variables. The drug has no effect on intraocular pressure in healthy subjects, but induces a significant @entity1 effect in @entity0 with @entity2 . This characteristic could be used for early diagnosis of primary @entity3 .

title: Effects of 2% XXXX on pupil, refraction, anterior segment anatomy and intraocular pressure.

answer: @entity4


abstract: BACKGROUND: To evaluate the safety and clinical efficacy of @entity5 anticoagulation after @entity1 alone for the treatment of @entity7 ( @entity7 ) complicated by old inferior vena cava (IVC) @entity3 . METHODS: From January 2008 to November 2013, 19 @entity7 @entity0 complicated with old IVC @entity3 were treated with @entity1 followed by oral administration of anticoagulant @entity5 . Follow-up was performed at 1 week, then 1, 2, 3, 6, and 12 months after @entity1 , and then annually thereafter. IVC patency and morphologic changes of the old @entity3 were examined by ultrasound, and clinical symptoms and signs were determined by clinical examinations during follow-up. RESULTS: Successful @entity1 was achieved in the 19 @entity0 (100%). Inferior vena cavography demonstrated the patency of IVC lumen, and the size of the old @entity3 was not altered. The mean pressure gradient between IVC and the right atrium was reduced from 27.5    3.0 cm @entity6 (range, 22-35) before treatment to 5.4    1.3 cm @entity6 (range: 2-7) after treatment (t = 41.6, P < 0.05; 1 cm @entity6 = 0.098 kPa). @entity0 were followed up as outpatients for an average of 15.9    14.4 months (range, 3-66). Anticoagulation with @entity5 was well tolerated in all @entity0 after @entity1 alone. Of the 19 @entity0 , complete resolution of the old @entity3 was achieved in 12 @entity0 and partial resolution was achieved in 7 @entity0 . Color Doppler ultrasound showed that 17 @entity0 had IVC lumen patency, and 2 @entity0 had @entity8 . None of the @entity0 had recurrence of @entity3 , symptomatic @entity4 , and @entity2 complications throughout the follow-up period. CONCLUSIONS: Our results indicate that @entity5 anticoagulation after @entity1 alone is a safe and effective therapy for @entity7 @entity0 with old IVC @entity3 .

title: Clinical outcomes of @entity5 anticoagulation after XXXX alone for the treatment of @entity7 complicated by old @entity3 .

answer: @entity1


abstract: INTRODUCTION: Surgical management of thoracolumbar @entity3 involves correction of @entity2 and placement of transpedicular instrumentation. The aim of this prospective cohort study was to generate first results reflecting the clinical and radiological outcome of @entity0 treated with percutaneous dorsal instrumentation for @entity4 of the thoracic and lumbar spine with the use of a transpedicular new Schanz Screw system (USS Fracture MIS, DePuy Synthes). METHODS: A total of 26 @entity0 with @entity4 of the thoracic and lumbar spine were operatively treated with bi-segmental dorsal instrumentation between January and December 2012. Radiological data acquisition was performed pre- and postoperatively, after six weeks, three, six, and twelve months. The radiological parameter of interest was the bi-segmental kyphotic end plate angle (Cobb angle). The @entity6 ( @entity6 ), the @entity6 Index (ODI), and the Spine Tango Core Outcome Measurement Index (COMI) were applied to investigate the clinical outcome. RESULTS: The clinical follow-up was completed by 22 @entity0 (84.6%), and the radiological follow-up by 21 (80.8%) @entity0 . Our @entity0 population had a mean age of 47.4    4.1 years. Twelve @entity0 received dorsal instrumentation, and 14 @entity0 were treated with an additional ventral reconstruction. Intraoperative reduction was 11.5    1.5   among all @entity0 (p < 0.01). A considerable amount of the operative correction was lost after six weeks with a @entity5 .6    1.4   (p < 0.01). At one year follow-up, the measured loss of reduction was significant in comparison to the postoperative state, 6.9    1.3   among all @entity0 , 8.7    2.1   after dorsal and 4.9    1.1   after dorsoventral stabilisation (all p < 0.01). Moreover, all @entity0 had minimal to moderate disability with a @entity6 of 1.8    0.4 (0 - 7), and an ODI of 15.6    3.6 (0 - 60). CONCLUSION: The new transpedicular Schanz screw system can deliver a correction and stabilization of thoracic and lumbar spine @entity4 . @entity0 report minimal to moderate disability as a result of their severe injury one year after @entity3 . We advocate the use of the transpedicular Schanz screw system to correct posttraumatic @entity2 , with secondary anterior fusion in our treatment strategy of thoracolumbar incomplete @entity4 in @entity0 without a @entity1 .

title: XXXX with a minimal-invasive transpedicular Schanz Screw system: clinical and radiological one-year follow-up.

answer: @entity4


abstract: The effect of @entity0 analogues on red-green opponent interaction was electrophysiologically investigated in anesthetized @entity1 ( @entity1 ). Two approaches were employed: amplitude measurement and principal component analysis. Electroretinograms were recorded for 23 monochromatic stimuli (400-700 nm) at an equal energy with white light adaptation before and after treatment with the @entity0 analogues, @entity2 , @entity3 , or both. Before treatment, although spectral amplitude curves of the a- and d-waves showed single, broad peaks at about 550 nm, the b-wave curve had three peaks at about 460, 540 and 600 nm, indicating the occurrence of the red-green opponent interaction. Principal component analysis performed on these waveforms extracted three components with short, middle, and long wavelength peaks, well defined characteristics of the red-green opponency. After vitreal injection of @entity2 , the a- and d-wave amplitudes were enhanced while the b-wave amplitude was almost completely diminished. However, principal component analysis showed basically similar characteristics to those before drug, suggesting that the red-green opponency was not affected. In contrast, after application of @entity3 , the a- and d-waves were diminished and the b-wave was enhanced as expected, however the enhancement was observed only in the short and middle wavelengths. As a result of this partial enhancement, the b-wave spectral amplitude curve showed only a single peak, unlike in the control. In addition, principal component analysis revealed a quite different result from the control; only two components with short and middle wavelength peaks and the component with long wavelength peak disappeared. Similar two components were also separated after the conjunction of both drugs. These results demonstrate that red-green opponency is greatly inhibited by @entity3 , and thus suggest that horizontal cells are related to a generation of the red-green opponency through a cone type selective or nonselective negative feedback.

title: Effect of XXXX analogues on red-green opponent interaction in monkey electroretinograms.

answer: @entity0


abstract: BACKGROUND: Cell-free DNA screen failure or "no calls" occur in 1-12% of samples and is frustrating for both clinician and @entity0 . The rate of no call has been shown to have an inverse relationship with gestational age. Recent studies have shown an increased risk for no calls among @entity1 @entity0 . OBJECTIVE: We sought to determine the optimal gestational age for cell-free DNA among @entity1 @entity0 . STUDY DESIGN: We performed a retrospective cohort study of @entity0 who underwent cell-free DNA at a single tertiary care center from 2011 through 2016. Adjusted odds ratios with 95% confidence intervals for a no call were determined for each weight class and for each weight class compared to normal-weight @entity0 . The predicted probability of a no call with 95% confidence intervals were determined for each week of gestation for normal-weight and @entity1 @entity0 and compared. RESULTS: Among 2385 @entity0 meeting inclusion criteria, 105 (4.4%) had a no call. Compared to normal-weight @entity0 , the adjusted odds ratio of a no call increased with increasing weight class from overweight to @entity1 class III (respectively: adjusted odds ratio, 2.31; 95% confidence interval, 1.21-4.42 to adjusted odds ratio, 8.55; 95% confidence interval, 4.16-17.56). A cut point at 21 weeks was identified for @entity1 class II/III @entity0 at which there is no longer a significant difference in the probability of a no call for @entity1 @entity0 compared to normal-weight @entity0 . From 8-16 weeks, there is a 4.5% reduction in the probability of a no call for  @entity1 class II/III @entity0 (respectively: 14.9%; 95% confidence interval, 8.95-20.78 and 10.4%; 95% confidence interval, 7.20-13.61; Ptrend < .01). CONCLUSION: The cut point of 21 weeks for optimal sampling of cell-free DNA limits reproductive choices. However, a progressive fall in the probability of a no call with advancing gestational age suggests that delaying cell-free DNA for @entity1 @entity0 is a reasonable strategy to reduce the probability of a no call.

title: XXXX and cell-free DNA "no calls": is there an optimal gestational age at time of sampling?

answer: @entity1


abstract: @entity0 stem cells (CSCs) are defined as a subset of slow cycling and undifferentiated cells that divide asymmetrically to generate highly proliferative, invasive, and chemoresistant @entity0 cells. Therefore, CSCs are an attractive population of cells to target therapeutically. CSCs are predicted to contribute to a number of types of @entity0 including those in the blood, brain, lung, gastrointestinal tract, prostate, and ovary. Isolating and enriching a @entity0 cell population for CSCs will enable researchers to study the properties, genetics, and therapeutic response of CSCs. We generated a protocol that reproducibly enriches for @entity1 CSCs from @entity1 cell lines (SKOV3 and OVCA429). Cell lines are treated with 20   M @entity2 for 3 days. Surviving cells are isolated and cultured in a serum-free stem cell media containing cytokines and growth factors. We demonstrate an enrichment of these purified CSCs by analyzing the isolated cells for known stem cell markers @entity4 , @entity3 , and @entity5 ( @entity5 ) and cell surface expression of @entity6 and @entity5 . The CSCs exhibit increased chemoresistance. This method for isolation of CSCs is a useful tool for studying the role of CSCs in chemoresistance and @entity0 relapse.

title: Enrichment for chemoresistant XXXX stem cells from human cell lines.

answer: @entity1